GCM
BPMC

Graham Capital Management’s Blueprint Medicines BPMC Stock Holding History

Graham Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,237
Closed -$552K – 1306
2025
Q1 		$552K Sell
6,237
-19,023
-75% -$1.86M 0.01% 763
2024
Q4 		$2.2M Buy
25,260
+8,283
+49% +$759K 0.03% 267
2024
Q3 		$1.57M Buy
16,977
+14,021
+474% +$1.39M 0.03% 349
2024
Q2 		$319K Sell
2,956
-30
-1% -$3K 0.01% 713
2024
Q1 		$283K Sell
2,986
-2,167
-42% -$186K 0.01% 806
2023
Q4 		$475K Sell
5,153
-2,746
-35% -$178K 0.01% 604
2023
Q3 		$397K Buy
+7,899
New +$422K 0.01% 630
2022
Q4 		– Sell
-17,195
Closed -$1.13M – 1063
2022
Q3 		$1.13M Sell
17,195
-42,878
-71% -$2.75M 0.04% 429
2022
Q2 		$3.03M Buy
60,073
+56,146
+1,430% +$3.29M 0.12% 113
2022
Q1 		$250K Buy
+3,927
New +$282K 0.01% 783

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Graham Capital Management's BPMC Position: Q2 2025 in Review

Graham Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 6,237 shares — an estimated $552K sold.

Graham Capital Management first reported a position in BPMC in Q1 2022 and held it in 10 quarters. The position peaked at $3.03M in Q2 2022. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Graham Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 6,237 Blueprint Medicines shares in Q2 2025, an estimated $552K.
  • Graham Capital Management first reported a position in Blueprint Medicines in Q1 2022 and held it in 10 quarters.
  • Graham Capital Management's Blueprint Medicines position peaked at $3.03M in Q2 2022.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.